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Nitrogen rich purine adduct (2) was prepared by reaction of 2,6-dichloro purine (1) with hydrazine hydrate was 
converted to hybrid purine-triazole ring (4) by a simple cyclisation process (con. HCl & methanol) on reaction with  
3-phenoxy benzaldehyde. The regioselectivity of synthesized adducts was carried out by simple spectroscopic techniques 
i.e. IR, 1H NMR & 13C NMR spectra. These studies gave an idea regarding replacement of chlorine out of C-2 or C-6 
position. Novelty was introduced by alkyl substation at N-9 position of imidazole ring and at –NH of triazole ring and a 
series of 4-chloro-5a,6-dihydro-1,6-dialkylated-8-(3-phenoxyphenyl)-1H-[1,2,4]triazolo[3,4-e]purine (5a-5g) hybrids were 
synthesized. 
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Analogous having acyclic part in core nucleoside 
structures are currently used as antiviral agents, 
cancer therapy, for the treatment of human 
immunodeficiency virus (HIV), hepatitis B (HBV), 
and herpes diseases1-3. These types of modification 
can be introduced by attachment of heterocyclic 
moieties, ribose moieties and by specific functional 
groups to the natural nucleoside
4
. 
1,2,3-Triazoles have been a fruitful source of 
inspiration for medicinal chemists for many years due 
to their synthetic accessibility by click chemistry as 
well as their numerous biological activities
5
. 1,2,3-
Triazole is a versatile moiety found in a large variety 















In modern antiviral and antitumor therapy, an 
important role is played by modified nucleosides and 
their analogs, in which modified purine structures are 
frequently found
12
. Human cells have the capacity to 
salvage purines and pyrimidines for the synthesis of 
deoxyribonucleotides that are used for the DNA 
synthesis, and analogues of these nucleotide 
precursors have proven to be an important class of 
anticancer agents
13
. There are total of 14 types of 
purine antimetabolites that are approved by the FDA 
for the treatment of cancer, which account for  
nearly 20% of all drugs that are used to treat cancer. 
Some of the first compounds approved by the FDA 
for the treatment of cancer were in this class of 
compounds14 (Figure 1). Several purine analogs have 
been evaluated for ATL. Among them, pentostatin has 
been most extensively evaluated as a single agent and 
in combination with other agents
15
. 
The traditional method for the synthesis of 2 or  
6- substituted purine analogues is the amination of 
halo, oxo, mercapto or methylmercapto groups with 
various amines, which can be performed smoothly in 
organic solvents (Bu-OH, CH3CN, dioxane, DMF, or 
DMSO) and in the presence of primary/ secondary/ 




Regioselectivity identification of any molecule is 
important in synthetic as well as pharmaceutical 
purpose. Regioselectivity in purine scaffolds were 
studied by many researchers at N-7 or N-9 
substitution17. Special efforts have been directed 
toward the synthesis of C-6 branched representatives 
by amine substitution in purine. In general current 
scenario is to diversify purine molecules by 
chloroamine coupling at C-6 position and couple of 
work was put forwarded to make such coupling at  






. Commonly, the preparation of such 
branched derivatives by direct ring formation in 
purine encounters difficulties due to the low reactivity 
of the pyrimidine ring nitrogen which does not favors 
cyclisation in all cases
19
. 
In this paper, we extended our research on purine 
base to modify it and generate a novel compounds to 
improve its significance
17, 18
. In a previous paper we 
reported N-9 substitution in purine skeleton by click 
chemistry to generate hybrid of purine-triazole 
derivatives. Here, we are reports an original short-cut 
to novel N-9 alkylated analogues of modified purine 
base and identify its regioselectivity towards 
replacement of chloro group by hydrazine hydrate and 
finally formation of triazoles at 2
nd
 position of purine 
based on the spectroscopic analysis i.e. IR, 
1
H NMR 
and 13C NMR spectra. 
 
Experimental Section 
Chemicals and solvents were purchased from the 
Sigma-Aldrich Chemical Co., Merck chemical, Finar 
and spectrochem Ltd. The entire chemicals were  
used without further purification. Thin-layer 
chromatography was accomplished on 0.2 mm 
precoated plates of Silica gel G60 F254 (Merck). 
Visualization was made under UV light (254 and 
365nm). IR spectra were recorded on an “IR Affinity-
1S spectrophotometer (Shimadzu)”. 
1
H (400 MHz) 
and 13C (101.1 MHz) NMR spectra were recorded on 
a “Bruker AVANCE II spectrometer” in DMSO-d6. 
Chemical shifts are expressed in δ ppms downfield 
from TMS. Mass spectra were determined by direct 
inlet probe on a “GC-MS-QP 2010 mass spectrometer 
(Shimadzu)”. Solvents were evaporated with a 
“BUCHI rotary evaporator”. Melting points were 
measured in open capillaries and are uncorrected. 
Procedure for the synthesis of 1-(6-chloro-9H-
purin-2-yl)hydrazine (2a). (Scheme I) 
To an oven dried single neck flask, the suspension 
of purine (1 mmol) and hydrazine hydrate (3.20 mmol) 
was stirred at room temprature (RT) for 30 mints 
(yellow color was turned to cream white color with 
hazy suspension after completion of the reaction). 



















































Figure 1 ― FDA approved and marketed purine antimetabolites 
 




layer chromatography using plain ethyl acetate as  
a mobile phase. After completion of the reaction,  
n-hexane was added to RBF and was filtered directly 
(photo sensitive material was isolated). The structure 
of product (2a) was confirmed by 
1
H NMR & 
13
C 
NMR spectroscopic techniques. 
1
H NMR (DMSO-d6, 400 MHz): δ 12.44 (1H, 
Broad-s, -NH of Imidazole ring), 9.19 (1H, s, -NH 
proton of hydrazine), 8.12 (1H, s, Methine proton of 
imidazole ring), 5.00-3.34 (2H, Broad-m, - NH2 of 
hydrazine group); 
13
C NMR (DMSO-d6, 101.1MHz): 
δ 154.84,152.27,151.79, 144.36 and 125.98. 
Procedure for the synthesis of 4-chloro-5a,6-
dihydro-8-(3-phenoxyphenyl)-1H-[1,2,4]triazolo 
[3,4-e]purine (4b). (Scheme II) 
To the previously prepared step I (Scheme I) (2a) 
product (2.0 mmol), 3-phenoxybenzaldehyde (2.0 
mmol) (3b) and concentrated hydrochloric acid (0.02 
mmol) were added in a methanol containing RBF.The 
reaction mixture was stirred at RT for 12.0 h. 
Completion of the reaction was monitored by TLC 
using three different mobile phase to identify product 
spot. After that reaction mixture was poured into ice 
crushed water and filtered using vaccum pump. To 
remove excess of acid, it was washed with cold water. 
Isolated dry product was used for the next step  
after crystallization in ethanol. Regioselectivity of 
compound 4b was identified by NMR techniques i.e. 
IR, 
1




H NMR (DMSO-d6, 400 MHz): δ 12.25-12.23 
(1H, d, -NH of Imidazole ring), 8.46 (1H, s, Methine 
proton of imidazole ring), 8.29 (1H, s, Pyrimidine 
ring C-2 proton), 7.73-7.71 (2H,d, Phenoxy ring 
proton), 7.50-7.41 (5H, m, Merging of -NH and 
phenoxy ring proton), 7.19-7.03 (4H, m, Phenoxy ring 
proton); 
13
C NMR (DMSO-d6, 101.1 MHz): δ 162.03, 
157.04, 156.87, 151.90, 150.00, 146.40, 136.62, 
130.27, 123.52, 122.36, 199.97, 118.54, 117.65, 
116.22, 115.95, 108.32. 
General procedure for the synthesis of 4-chloro-
5a,6-dihydro-1,6-dialkylated-8-(3-phenoxyphenyl)-
1H-[1,2,4]triazolo[3,4-e]purine (5a-5g). (Scheme III) 
For the preparation of final adduct, step II (Scheme 
II) (4b) (1.0 mmol), dry K2CO3 powders (3.5 mmol) 
were mixed in DMF containing vessel. After 1.0 h 
heating at 70
o
C temperature, alkyl bromide (2.25 
mmol) was added and it was further heated for 2.0 h. 
After completion of the reaction (monitored by TLC), 
reaction mixture was poured into ice cold water and 










































Scheme II — (b) Methanol, Conc. HCl, 12.0 h 




Purification of final molecules was carried out by 
column chromatography by using silica gel (60-120 
mesh) in a Hexane: Ethyl acetate (8:2) as a mobile 
phase. Identification and characterization of derived 
scaffolds (5a-5g) were carried out by various 







This compound was obtained as off white colored 
powder; Yield: 92%; mp (melting point): 198°C; IR 
(cm
-1
): 3107 (Aromatic C-H Stretch), 3030 (Alkane 
C-H stretch; Asym.), 2955 (Alkane C-H stretch; 
Sym.), 1699 (C=N Stretch), 1559, 1488, 1444 
(Aromatic ring skeleton), 1321 (C-N Stretch of 
aromatic amines), 782 (C-Cl Stretch); 
1
H NMR 
(DMSO-d6, 400 MHz): δ 8.56-8.54 (d, 2H, imidazole 
and triazole =CH proton), 7.80 (s, 1H), 7.80-7.78 (d, 
1H), 7.51-7.45 (m, 3H), 7.22-7.20 (d, 1H), 7.19-7.16 
(m, 2H), 7.09-7.06 (m, 1H), 3.60 (s, 3H, -Me attached 
to imidazole ring –NH), 2.99 (s,3H, -Me attached to 
triazole ring –NH); 
13
C NMR (DMSO-d6, 101.1 
MHz): δ 160.04,157.29, 154.17, 153.13, 152.31, 
144.24, 140.75, 138.99, 131.19, 124.73, 123.05, 







This compound was obtained as white colored 
powder; Yield: 94%; mp: 210°C; IR (cm-1): 3104 
(Aromatic C-H Stretch), 3020 (Alkane C-H stretch; 
Asym.), 2942 (Alkane C-H stretch; Sym.), 1681 (C=N 
Stretch), 1563, 1495, 1450 (Aromatic ring skeleton), 
1324 (C-N Stretch of aromatic amines), 776 (C-Cl 
Stretch); 1H NMR (DMSO-d6, 400 MHz): δ 8.19-8.18 
(d, 2H, imidazole and triazole =CH proton), 7.76 (s, 
1H), 7.79-7.77 (d, 1H), 7.48-7.42 (m, 3H), 7.25-7.23 
(d, 1H), 7.00-6.99 (m, 2H), 6.80-6.74 (m, 1H), 3.86-
3.84 (q, 2H, ethyl CH2 attached to imidazole ring –
NH), 3.40-3.36 (q, 2H, ethyl CH2 attached to triazole 
ring –NH), 1.51-1.49 (t, 3H, terminal –Me attached to 










































Scheme III — (c) R-Br, DMF, Dry K2CO3, 70
oC Temp., 3.0 h 
 






C NMR (DMSO-d6, 101.1 MHz): δ 
157.98, 155.69, 153.58, 152.43, 151.50, 144.89, 
140.42, 138.61, 132.68, 126.46, 123.28, 120.95, 






This compound was obtained as dark red colored 
oily mass; Yield: 95%; IR (cm
-1
): 3110 (Aromatic C-
H Stretch), 3036 (Alkane C-H stretch; Asym.), 2942 
(Alkane C-H stretch; Sym.), 1690 (C=N Stretch), 
1561, 1483, 1441 (Aromatic ring skeleton), 1319 (C-
N Stretch of aromatic amines), 771 (C-Cl Stretch); 
1
H 
NMR (DMSO-d6, 400 MHz):δ 8.22-8.21 (d, 2H, 
imidazole and triazole =CH proton), 7.85 (s, 1H), 
7.77-7.75 (d, 1H), 7.51-7.45 (m, 3H), 7.29-7.27 (d, 
1H), 7.12-7.09 (m, 2H), 7.09-7.06 (m, 1H), 4.40-4.37 
(t, 2H, propyl first CH2 attached to imidazole ring –
NH), 3.02-2.99 (t, 2H, propyl first CH2 attached to 
triazole ring –NH), 1.58 (m, 4H), 1.10 (m, 6H); 
13
C 
NMR (DMSO-d6, 101.1MHz): δ 159.23, 157.40, 
154.57, 153.10, 152.00, 145.27, 144.23, 139.04, 
132.04, 125.09,121.17, 120.27, 118.27, 117.08, 52.68, 






This compound was obtained as dark red colored 
oily material; Yield: 97%; IR (cm-1): 3100 (Aromatic 
C-H Stretch), 3029 (Alkane C-H stretch; Asym.), 
2954 (Alkane C-H stretch; Sym.), 1666 (C=N 
Stretch), 1563, 1493, 1446 (Aromatic ring skeleton), 
1310 (C-N Stretch of aromatic amines), 770 (C-Cl 
Stretch); 
1
H NMR (DMSO-d6, 400 MHz): δ 8.16-8.15 
(d, 2H, imidazole and triazole =CH proton), 7.76 (s, 
1H), 7.71-7.69 (d, 1H), 7.43-7.38 (m, 3H), 7.16-7.14 
(d, 1H), 7.07-7.04 (m, 2H), 7.03-7.00 (m, 1H), 5.84 
(s, 1H, triazole ring side), 5.07 (s, 2H, -CH2 attached 
to imidazole ring –NH), 4.43 (s, 2H, -CH2 attached to 
triazole ring –NH), 2.34 (s, 1H, imidazole ring side); 
13C NMR (DMSO-d6, 101.1MHz):δ 157.99, 155.91, 
154.05, 153.13, 152.95, 144.19, 141.59, 138.66, 
132.03, 125.88, 123.00, 120.30, 118. 8, 117.40,75.68, 






This compound was obtained as off white colored 
floppy powder; Yield: 87%; mp: 179°C; IR (cm
-1
): 
3101 (Aromatic C-H Stretch), 3040 (Alkane C-H 
stretch; Asym.), 2951 (Alkane C-H stretch; Sym.), 
1682 (C=N Stretch), 1541, 1471, 1425 (Aromatic ring 
skeleton), 1330 (C-N Stretch of aromatic amines), 773 
(C-Cl Stretch); 
1
H NMR (DMSO-d6, 400 MHz): δ 
8.21-8.20 (d, 2H, imidazole and triazole =CH proton), 
7.90 (s, 1H), 7.82-7.80 (d, 1H), 7.54-7.48 (m, 3H), 
7.31-7.29 (d, 1H), 7.16-7.13 (m, 2H), 7.11-7.08 (m, 
1H), 4.44 (m, 1H), 3.58 (m, 1H), 1.76 (m, 6H), 1.21 











































C NMR (DMSO-d6, 101.1MHz):δ 157.20, 
156.99, 154.49, 154.01, 152.69, 145.06, 140.89, 
139.55, 132.29, 124.58, 123.91, 120.86, 119.55, 







This compound was obtained as light yellow 
colored solid powder; Yield: 89%; mp: 196°C; IR 
(cm
-1
): 3111 (Aromatic C-H Stretch), 3023 (Alkane 
C-H stretch; Asym.), 2949 (Alkane C-H stretch; 
Sym.), 1695 (C=N Stretch), 1561, 1485, 1442 
(Aromatic ring skeleton), 1331 (C-N Stretch of 
aromatic amines), 775 (C-Cl Stretch); 
1
H NMR 
(DMSO-d6, 400 MHz): δ 8.31-8.29 (d, 2H, imidazole 
and triazole =CH proton), 7.79 (s, 1H), 7.71-7.69 (d, 
1H), 7.49-7.43 (m, 3H), 7.15-7.13 (d, 1H), 7.08-7.03 
(m, 2H), 6.99-6.94 (m, 1H), 4.87 (m, 1H, -CH 
attached to imidazole ring –NH), 3.80 (m, 1H, -CH 
attached to triazole ring –NH), 1.70 (m, 2H, -CH2 of 
imidazole ring side), 1.43 (m, 2H, - CH2 of triazole 
ring side), 1.34 (d, 6H, branched -CH3), 1.01 (m, 6H, 
terminal both –CH3); 
13
C NMR (DMSO-d6, 
101.1MHz):δ 159.59,157.36, 154.66, 153.56, 151.89, 
143.22, 139.98, 137.65, 128.97, 122.78, 121.28, 
118.99, 117.90, 111.29, 65.29, 58.66, 29.99, 23.12, 






This compound was obtained as cream white 
colored powder; Yield: 91%; mp: 204°C; IR (cm
-1
): 
3112 (Aromatic C-H Stretch), 3029 (Alkane C-H 
stretch; Asym.), 2954 (Alkane C-H stretch; Sym.), 
1690 (C=N Stretch), 1558, 1480, 1446 (Aromatic ring 
skeleton), 1322 (C-N Stretch of aromatic amines), 779 
(C-Cl Stretch); 
1
H NMR (DMSO-d6, 400 MHz): δ 
8.20-8.19 (d, 2H, imidazole and triazole =CH proton), 
7.81 (s, 1H), 7.76-7.74 (d, 1H), 7.48-7.42 (m, 3H), 
7.21-7.19 (d, 1H), 7.11-7.08 (m, 2H), 7.06-7.03 (m, 
1H), 4.38 (s, 2H, butane first CH2 attached to 
imidazole ring –NH), 4.17-4.13 (t, 2H, butane first 
CH2 attached to triazole ring –NH), 1.79-1.75 (t, 2H), 
1.62-1.60 (d, 2H), 1.40-1.36 (t, 2H), 1.28-1.22 (q, 
2H), 0.96-0.88 (m, 6H: 3H+3H- two multiplet); 13C 
NMR (DMSO-d6, 101.1MHz):δ 157.24,156.41, 
153.55, 153.13, 151.36, 143.07, 139.58, 137.64, 
130.09, 123.64, 122.90,119.36, 119.09, 116.41, 42.80, 
41.79, 31.11, 27.07, 19.48, 19.16, 13.64, 13.34; Mass 
(m/z): 476.20 (M+). 
Results and Discussions 
Initially, on the basis of our previous work we 
concluded that the nucleophile attacks(-NH2) 
preferred in purine at on C-6 position of pyrimidine 
ring
18
 but we were surprised that the attack of 
hydrazine was at C-2 position and replaced the chloro 
group. The preparations of our targeted scaffolds (5a-
5g) were achieved in three steps. Treatment of purine 
(1 mmol) with hydrazine hydrate (without any 
solvents) (3.20 mmol) under room temperature 
stirring gave step I product (2a) (Scheme I) which on 
reaction with 3-phenoxy benzaldehyde (2.0 mmol) in 
acidic condition followed by N-alkylation (R-X, 4.10 
mmol) in purine imidazole ring –NH using traditional 
conditions [DMF, dry-powdered K2CO3 (3.5 mmol)] 
gave interesting novel molecules (5a-5g). Purine-
hydrazide (2a) was obtained in 98% yield in 30 min 
by this reaction but the material isolated wasphoto 
sensitive. It is mandatory to mention over here is the 
need for more attention during the time of completion 
and during work up procedure as it would turned red 
in color by letting it stand in the reaction vessel with 
hydrazine or open in air for prolonged time. However, 
when 2a was treated with 3-phenoxy benzaldehyde 
without acidic media at room temperature, the 
cyclisation reaction was comparatively slow and took 
a longer time (18 h) to afford 4b in only 60% yield 
(Scheme IV). Some selected results of the screening 
of the reaction with catalysts or without catalysts and 
optimized conditions for the reaction under this study 
are presented in Table I and Table II. Among them the 
following features draw attention: By observed in 
Table I, entry 10, it is clear that hydrazine hydrate in 
3.20 mmol ratio and also it acts as a solvent gave 
excellent yield in a short time.  
Table I, entry 1-12 gave a conclusion that CuI is 
better catalyst than the proline for chloro-amine 
coupling but it’s took longer time. And the amount of 
product was the same either we used CuI or without 
any catalyst. In short, it seemed better not to use any 
catalyst as there was no any effect in % of yield.  
By the viewing entry 10 and entry 12 (Table I), it is 
evident that 3.20 mmol of hydrazine is the maximum 
amount required and increasing beyond it does not 
affect the time of the completion of the reaction.  
Table II gave a general idea regarding types of 
catalysts and their effects on product yields. All the 
four entry shows that methanol gave higher yield as 
compared to other by using con. HCl as catalyst 
(Entry 1). 




The step II was also performed without using 
catalyst (con. HCl) and it could be concluded that the 
reaction has progressed but required more than 24 h to 
complete and the yield was in the range of 88-92%.  
 
Reaction Scheme 
Preparation of purine-triazole adducts (5a-5g). 
Literature review reveals that, amine substitution 
would be preferably being at C-6 chlorine of the 
pyrimidine ring in purine
18
. Although shielding and 
deshielding effect in NMR spectra of the product (4b) 
direct us to infer the substitution of hydrazine at C2- 
Cl (Structure (a)) and triazole ring formation was take 
place. Ideally predicted C2-H (Structure (a)) PMR 
value should be ~8.2 δppm if substitution of 
hydrazine take place at C2-C1 and if substitution of 
hydrazine take place at C6-C1, so C6-H (Structure 
(b)) value should be ~5.0 δppm after triazole ring 
formation in purine. But in final adduct 
1
H NMR 
(Supplementary Information) shows value at  
8.2 δ ppm (for C2-H proton) which confirm that  
C2-Cl was substituted by hydrazine. 
In addition, 
13
C NMR also helps to define 
regioselectivity of intermediate product (4b) by 
studying 
13
C chemical shift of following two 
structures [Figure. 2 (a) and Figure. 2 (b)] to confirm 
the orientation of ring formation. Predicted 
13
C NMR 
value of C-4 and C-5 should be at ~156 and ~142 δ 
ppm respectively, if structure (a) was possible. In 
opposite case, if structure (b) was possible than  
the 
13
C NMR value for C-4 and C-5 should be at  
~142 and ~115 δ ppm respectively, due to the 
difference in electronegative nuclei attached to the  
C-6. On looking at thecompound (4b) 
13
C NMR 
spectra (Supplementary Information) gave C-4 and  
C-5 peak at 156.36 and 146.40 δ ppm respectively. 
This value was near to the predicted 
13
C NMR value 
of the structure (a). 
Chemically three possibilities for regioselective 
nature was put forwarded on the basic of IR and 
1
H 
NMR spectroscopy. First possible adduct may be by 
the removal of two protonsi.e. C2-H proton of purine 
ring and –NH
11
 proton of triazole ring, and formation 
of double bond in the presence of basic media (Dry 
K2CO3) (5h). Second possibility may be obtained by 
alkylation at only the imidazole ring –NH and triazole 
ring –NH remains unblocked by alkyl halides (5j). 
And third possibility surprised us with the alkyl group 
being attached at both the –NH i.e. imidazole ring  
and triazole ring (5j) (Scheme IV, Step III). First and 
third possibilities was dated out on the basis of IR 
study (Supplementary Information) as it has been 
concluded that in final products (5a-5g) –NH 
frequency has disappeared and no frequency was 
found at ~3300 cm
-1
 and also presence of almost 
double proton peak corresponding to alkyl group in 
1H NMR. Now second criteria (5i) for possible 
adducts exactly fit on the basis of IR and 
1
H NMR 
study and the reason behind this was above two 
conclusion about –NH frequency and NMR protons of 
the alkyl groups. 
 
Table II — Synthesis of adduct 4b [Step II, 2a (2.0 mmol); 
3-Phenoxybenzaldehyde (2.0 mmol), RT] 
Entry Solvents Catalyst Yield 
1 Me-OH Con. HCl 96% 
2 Et-OH Con. HCl 89% 
3 H2O Con. HCl 58% 
4 DMSO Con. HCl 62% 
 
 
Table I ― Synthesis of adduct 2a [Purine, 1a (1 mmol), RT] 
Entry Hydrazine, mmol Solvents Catalysts, mol %; Time Isolated, Yielda(%) 
1 1.0 Water, 2 ml Nonec Prolineb, 20 - 
2 1.0 None Noneb CuI, 20; 5 h - 
3 1.5 Methanol, 2 ml Nonec Prolinec, 15 - 
4 1.5 None Nonec CuI, 15; 5 h - 
5 2.0 Methanol, 2 ml None* Prolineb, 20 52 
6 2.0 None None; 2 h CuI, 10; 3 h 89 
7 2.5 Methanol, 2 ml None* Prolineb, 20 80 
8 2.5 None None; 1 h CuI, 5; 3 h 91 
9 3.2 Methanol, 2 ml None* Prolinec, 20 90 
10 3.2 None None; 30 Mints CuI, 5; 2 h 98 
11 5.0 Methanol, 2 ml None* Prolinec, 20 80 
12 5.0 None None; 30 Mints CuI, 5; 2 h 98 
aYield expressed in reaction which performed without using any catalysts; bNot observed any progress in the reaction; cYield of product is 
less than 10%; *Reaction not complies after stirring of 24 h. 
 





It was realize that purine gave a variant look if we 
substitute the chlorine by differentamine. Purine 





C NMR and concluded that triazole ring 
formation has taken place at C-2 carbon atom. 
Novelty of the product was introduced by alkyl 
substitution in imidazole ring –NH to make a better 
nucleotide to enhance pharmaceutical applications. 
Surprising results areobserved in the final step 
(alkylation in imidazole ring) that -NH group of 
triazole ring was alkylated by the removal of the 




Supplementary information is available in the 
website http://nopr.niscair.res.in/handle/123456789/60. 
For the confirmation of spectral discussion see the 
spectra of the representative compound in 
Supplementary information. 
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